Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bacterial translocase inhibitors - Sankyo/Sequella

Drug Profile

Research programme: bacterial translocase inhibitors - Sankyo/Sequella

Alternative Names: SQ641; SQ922

Latest Information Update: 05 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Sequella
  • Class Aminoglycosides; Anti-inflammatories; Antibacterials; Nucleosides
  • Mechanism of Action Phospho-N-acetylmuramoyl pentapeptide transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium-difficile-infections; Crohn's disease
  • Discontinued Mycobacterial infections

Most Recent Events

  • 05 Feb 2018 SQ 641 is still in preclinical development for Crohn's disease in USA
  • 05 Feb 2018 Discontinued - Preclinical for Mycobacterial infections in USA (unspecified route)
  • 05 Feb 2018 Preclinical trials in Clostridium difficile infections in USA (unspecified route) (Sequella pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top